Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

These Two Stocks Are in the Spotlights and Hedge Funds Suggest One of Them is a Buy

Page 1 of 2

Alkermes Plc (NASDAQ:ALKS) and Apollo Education Group Inc (NASDAQ:APOLare in the news after the FDA approved Alkermes Plc’s ARISTADA for the treatment of schizophrenia while Apollo announced Gregory Iverson will replace Joseph D’Amico as the company’s permanent chief financial officer. Shares of Alkermes are up 6.24% while shares of Apollo are unchanged in after hours trading. Let’s take a closer look at the two companies and see whether the hedge fund sentiment towards them suggest any trading opportunities.

Teva Pharmaceuticals TEVA Drugs

Most investors don’t understand hedge funds and indicators that are based on hedge funds’ activities. They ignore hedge funds because of their recent poor performance in the bull market. Our research indicates that hedge funds underperformed because they aren’t 100% long. We uncovered that hedge funds’ long positions actually outperformed the market. For instance the 15 most popular small-cap stocks among funds beat the S&P 500 Index by more than 60 percentage points since the end of August 2012. These stocks returned a cumulative of 118% vs. a 58% gain for the S&P 500 ETF (SPY) (read more details). That’s why we believe investors should pay attention to what hedge funds are buying (rather than what their net returns are).

Follow Alkermes Inc (NASDAQ:ALKS)
Trade (NASDAQ:ALKS) Now!

Alkermes Plc (NASDAQ:ALKS)‘s ARISTADA extended-release injectable suspension is important because it is the first antipsychotic with six-week and once-monthly options for maintaining and delivering therapeutic levels of medication in the body through injection. The longer duration ensures a better compliance, although a medical professional will still have to administer the drug. The schizophrenia treatment is a billion dollar market, and analysts are optimistic about the company’s prospects. Eight analysts have a ‘Buy’ rating, one has a ‘Sell’ rating, and three have a ‘Hold’ rating. Morgan Stanley has an ‘Overweight’ rating with a $85 price target while JPMorgan Chase & Co has a ‘Buy’ rating with a $77 price target. Cowen and Company has a ‘Buy’ rating with a $80 price target. Overall, analysts have a consensus price target of $69.96, giving shares an upside of 17.04% from current levels.

In addition to ARISTADA, Alkermes also has ALKS 5461, a potential treatment for depression, and ALKS 8700, a potential treatment for multiple sclerosis, in its pipeline. If all goes well, Alkermes could have multiple blockbuster drugs in the years to come. Shares are up 8% year to date after rallying from less than $10 in 2010.

However, Alkermes Plc (NASDAQ:ALKS) still has to win the support of hedge funds. Although the number of funds decreased to 25 from 27 during the third quarter, the total value of their holdings in the stock increased to $284.69 million from $207.1 million, but it was equal to only 3% of the company at the end of June. More specifically, Ken Griffin‘s Citadel Investment Group increased its position by 115% to 1.27 million shares, while Justin John Ferayorni’s Tamarack Capital Management raised its holding by 67% to 400,000 shares. Going the other way was D. E. Shaw, which lowered its stake by 26% to 188,649 shares. Currently, some 5.44% of the drug company’s float is short.

Follow Apollo Education Group Inc (NASDAQ:APOL)
Trade (NASDAQ:APOL) Now!

Apollo Education Group Inc (NASDAQ:APOL), one of the world’s largest private education providers, announced that it will promote Gregory Iverson to CFO. Apollo Education could use some new management, as its shares are down 66% year to date so far. The company’s revenue is off substantially from 2013 as enrollment remains weak and the FTC investigates the company’s business practices. Education is in dire need of change, but Apollo in its current state isn’t exactly playing the role of disruptor.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!